Evidence-based dosage guides, reconstitution protocols, and side-effect research for the research community.
Research-reported ranges for the BPC-157 and TB-500 pairing often called the wolverine stack, plus reconstitution math.
Read guide →Half-life, GH pulse shape, and the human evidence separate tesamorelin from CJC-1295 with and without DAC.
Read guide →Visceral-fat trials in HIV lipodystrophy cut deep abdominal fat by about 15 percent without much weight loss, and the change faded after treatment stopped.
Read guide →Cognition, ischemia models, and optic nerve research: what the Semax literature actually covers, and what it does not.
Read guide →How a GHRH analog and a selective ghrelin-receptor agonist can amplify one GH pulse, and why no combined clinical dose exists.
Read guide →How N-terminal acetylation and C-terminal amidation change Semax, what the parent peptide literature supports, and where the evidence stops.
Read guide →A research reference covering ipamorelin's GH-releasing selectivity, body composition, bone density, and recovery findings from preclinical studies.
Read guide →A research reference summarizing selank dose figures from animal studies and human pilot trials, covering intranasal and subcutaneous routes.
Read guide →A research overview of CJC-1295's mechanism, how it stimulates pulsatile GH secretion, and the difference between DAC and non-DAC forms.
Read guide →A research overview of tesamorelin side effects, from injection site reactions and fluid retention to IGF-1 elevation and glucose considerations researchers monitor.
Read guide →A research-based overview of hypoglycemia risk, water retention, and other effects documented for IGF-1 LR3 in preclinical models.
Read guide →Tesamorelin holds a narrow FDA authorization for HIV-associated lipodystrophy. This guide explains what the approval covers, what falls outside it, and what study data shows.
Read guide →How MOTS-c activates AMPK, regulates glucose uptake, translocates to the nucleus under stress, and why researchers study it as a metabolic and longevity signal.
Read guide →Research-reported schedules for MOTS-c administration, including daily vs. alternate-day protocols, timing windows, and cycle lengths.
Read guide →A research overview of Thymosin Beta-4: mechanisms of action including actin regulation, angiogenesis, and tissue repair.
Read guide →SubQ vs. intramuscular routes, site rotation protocols, intranasal delivery for neuropeptides, and volume considerations for common research peptides.
Read guide →How CPPs interact with model cell membranes, deliver research cargo, and why uptake, endosomal escape, and toxicity need to be measured separately.
Read guide →The math behind peptide reconstitution, a reference table of vial sizes and BAC water volumes, and peptide-specific notes for BPC-157, TB-500, CJC-1295, and IGF-1 LR3.
Read guide →A research reference covering preclinical changes in lean mass, body composition, tissue repair markers, and IGF axis biomarkers observed before and after IGF-1 LR3 exposure in animal models.
Read guide →A consolidated reference chart covering study quantities, frequency, route, and cycle length for BPC-157, TB-500, CJC-1295, ipamorelin, IGF-1 LR3, MOTS-c, tesamorelin, SS-31, and DSIP.
Read guide →How BPC-157 modulates inflammatory pathways in preclinical models, from gut colitis to joint and tendon injury.
Read guide →What peptides are, how they differ from proteins, and the main research categories.
Read guide →Step by step: turn vial size, water volume, and target dose into an exact injection amount.
Read guide →How to mix lyophilized peptides with bacteriostatic water, safely and accurately.
Read guide →What the research literature reports on BPC-157 tolerability and safety signals.
Read guide →Research-reported BPC-157 dosing ranges in a clear reference chart.
Read guide →A research overview of BPC-157 and tissue, tendon, and gut repair studies.
Read guide →Research protocols and a loading vs maintenance dosing chart for TB-500.
Read guide →What studies and reports say about TB-500 tolerability.
Read guide →Common research-reported effects of CJC-1295 and what drives them.
Read guide →How CJC-1295 is studied in the context of growth hormone and lean mass.
Read guide →Why CJC-1295 and ipamorelin are researched together, with a dosing reference.
Read guide →Research dosing ranges and handling notes for IGF-1 LR3.
Read guide →Research-reported tesamorelin dosing and a reference chart.
Read guide →The mechanism of tesamorelin as a GHRH analog, explained.
Read guide →Two growth hormone peptides compared by mechanism, use, and profile.
Read guide →A MOTS-c dosing chart and protocol overview for research.
Read guide →What early research reports about MOTS-c tolerability.
Read guide →What research and reports describe over a MOTS-c study period.
Read guide →Research dosing ranges for the mitochondrial peptide SS-31 (elamipretide).
Read guide →Research dosing notes for delta sleep-inducing peptide (DSIP).
Read guide →